Mango improves glucose and lipid parameters in mice fed high fat diet.

Mangoes contain high amounts of beta carotene, vitamin C, and phenolic compounds that may confer cardiovascular health benefits. The objective of this study is to compare the effects of freeze dried mango with a known PPARγ agonist, rosiglitazone (rosi), and a known PPARα agonist, fenofibrate (feno), in modulating glucose and lipid parameters using a mouse model of diet‐induced obesity. Eight wk old male C57BL/6 mice were randomized into 6 treatment groups (n=25/group): control diet, high fat (HF) diet, HF + 1% mango (w/w), HF + 10% mango (w/w), HF + rosi (50mg/kg diet), and HF + feno (500mg/kg diet). Dietary treatment lasted for 8 or 16 wks. At both time points, HF fed mice had the highest fat mass and the two doses of mango were comparable to rosiglitazone in attenuating the increase in fat mass due to HF diet. Similar to rosiglitazone, mango modulated the rise in plasma glucose, cholesterol, and NEFA associated with HF diet for 8 wks but no treatment effects were observed after 16 wks. Mice on the low dose mango diet for 8 wks had the best response after a glucose challenge. Plasma leptin was significantly elevated in the HF group after 8 wks of dietary treatment which was modulated by rosiglitazone, fenofibrate, and the two doses of mango. Fenofibrate caused an enlargement of liver which was not observed with the other treatments. These findings suggest that mango may be beneficial in lowering risk factors of cardiovascular disease. (Supported by the Mango Board and College of Human Environmental Sciences, Oklahoma State University)